Literature DB >> 9463674

The efficacy of benzimidazole drugs against Plasmodium falciparum in vitro.

T S Skinner-Adams1, T M Davis, L S Manning, W A Johnston.   

Abstract

The sensitivities in vitro of Plasmodium falciparum to the benzimidazoles, albendazole, thiabendazole, mebendazole, omeprazole and 2 albendazole metabolites, albendazole sulphone and albendazole sulphoxide, were investigated and compared to those of the commonly used antimalarial drugs chloroquine and quinine. Quinine and chloroquine were the most potent drugs tested (EC50 values of 8 x 10(-9)-6 x 10(-8) mol/L and 5-7 x 10(-9) mol/L, respectively). Thiabendazole, mebendazole, albendazole sulphone and albendazole sulphoxide reached maximum growth inhibitions of 13-36% at the highest concentration tested (1 x 10(-4) mol/L). Albendazole (EC50 range: not achieved-2 x 10(-6) mol/L) and omeprazole (EC50 range: 2-4 x 10(-5) mol/L) were the most effective benzimidazoles. The activity of albendazole was pH dependent, as was that of chloroquine, and variable. Albendazole has its primary mode of action on trophozoites, suggesting that the drug may target parasite tubulin polymerization. Omeprazole, although also primarily effective against trophozoites, had additional activity against schizonts and ring forms, suggesting a distinct or additional parasitic target. Given the variable activity of albendazole and its rapid metabolism in vivo into compounds with even less antimalarial activity, it appears unlikely that this benzimidazole will be useful in the treatment of malaria. The rapid activity and different stage-specific profile of the more soluble benzimidazole omeprazole warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9463674     DOI: 10.1016/s0035-9203(97)90035-3

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  17 in total

Review 1.  Cytoskeleton of apicomplexan parasites.

Authors:  Naomi S Morrissette; L David Sibley
Journal:  Microbiol Mol Biol Rev       Date:  2002-03       Impact factor: 11.056

2.  Synergistic in vitro antimalarial activity of omeprazole and quinine.

Authors:  T Skinner-Adams; T M Davis
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Efficacy of proton pump inhibitor drugs against Plasmodium falciparum in vitro and their probable pharmacophores.

Authors:  Michael A Riel; Dennis E Kyle; Apurba K Bhattacharjee; Wilbur K Milhous
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 4.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

5.  Malaria-infected mice live until at least day 30 after a new artemisinin-derived thioacetal thiocarbonate combined with mefloquine are administered together in a single, low, oral dose.

Authors:  Alexander M Jacobine; Jennifer R Mazzone; Rachel D Slack; Abhai K Tripathi; David J Sullivan; Gary H Posner
Journal:  J Med Chem       Date:  2012-08-27       Impact factor: 7.446

6.  Hemozoin inhibiting 2-phenylbenzimidazoles active against malaria parasites.

Authors:  Fabrizio P L'abbate; Ronel Müller; Roxanne Openshaw; Jill M Combrinck; Katherine A de Villiers; Roger Hunter; Timothy J Egan
Journal:  Eur J Med Chem       Date:  2018-09-28       Impact factor: 6.514

7.  Rationale for the coadministration of albendazole and ivermectin to humans for malaria parasite transmission control.

Authors:  Kevin C Kobylinski; Haoues Alout; Brian D Foy; Archie Clements; Poom Adisakwattana; Brett E Swierczewski; Jason H Richardson
Journal:  Am J Trop Med Hyg       Date:  2014-07-28       Impact factor: 2.345

8.  The effect of anthelmintic treatment during pregnancy on HIV plasma viral load: results from a randomized, double-blind, placebo-controlled trial in Uganda.

Authors:  Emily L Webb; Jacqueline Kyosiimire-Lugemwa; Dennison Kizito; Peter Nkurunziza; Swaib Lule; Lawrence Muhangi; Moses Muwanga; Pontiano Kaleebu; Alison M Elliott
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

9.  Impact of anthelminthic treatment in pregnancy and childhood on immunisations, infections and eczema in childhood: a randomised controlled trial.

Authors:  Juliet Ndibazza; Harriet Mpairwe; Emily L Webb; Patrice A Mawa; Margaret Nampijja; Lawrence Muhangi; Macklyn Kihembo; Swaib A Lule; Diana Rutebarika; Barbara Apule; Florence Akello; Hellen Akurut; Gloria Oduru; Peter Naniima; Dennison Kizito; Moses Kizza; Robert Kizindo; Robert Tweyongere; Katherine J Alcock; Moses Muwanga; Alison M Elliott
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

10.  Treatment with anthelminthics during pregnancy: what gains and what risks for the mother and child?

Authors:  Alison M Elliott; Juliet Ndibazza; Harriet Mpairwe; Lawrence Muhangi; Emily L Webb; Dennison Kizito; Patrice Mawa; Robert Tweyongyere; Moses Muwanga
Journal:  Parasitology       Date:  2011-08-03       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.